Oct 10, 2026 · 12 min
mRNA flu vaccine faces access and preparedness hurdles
The science and politics of the new mRNA flu vaccine
The vaccine’s faster manufacturing does not yet mean faster strain updates, while coverage gaps could limit access and weaken future pandemic readiness.
- 1Moderna’s mRNA flu vaccine uses the same strains as traditional vaccines because selection still follows existing regulatory schedules.
- 2Side effects resemble those of other flu vaccines, but insurance uncertainty and a potential $100-plus price may restrict access.
- 3Reduced U.S. investment could leave the country less prepared to produce vaccines domestically during a future pandemic.
Don't miss
Anna P. Durbin explains that a vaccine designed for faster updating still follows a strain-selection system that has not sped up.
The brief
Moderna’s newly approved mRNA flu vaccine promises quicker manufacturing, but Anna P. Durbin says it uses the same strains as traditional vaccines.
Flu strain selection still depends on twice-yearly World Health Organization and Food and Drug Administration meetings, so mRNA speed has not changed the timetable.
Durbin describes familiar side effects, including fatigue, muscle aches, redness, and low-grade fever, while lipid nanoparticles help stimulate the immune response.
The vaccine is available at pharmacies, but the absence of an active ACIP recommendation creates uncertainty about insurance coverage; uninsured patients may pay more than $100.
The broader concern is strategic: with less U.S. investment in mRNA technology than Europe and China, domestic production could lag during a future pandemic.